15 completed, 14 terminated, 2 recruiting, 2 withdrawn. 35 Phase 2, 9 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 35 | Completed 15, Terminated 14, Recruiting 2, Withdrawn 2, Active not recruiting 1, Unknown 1 |
| Phase 1 | 9 | Terminated 5, Completed 3, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow Stem Cell Infusion: new trials by email Literature Review of Stem Cell Infusion trials Research Report on Stem Cell Infusion
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases Treosulfan, Fludarabine, Total Body Irradiation - AML, MDS | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 132 | 2026-04-10 | 2026-04-16 |
| Siplizumab for Sickle Cell Disease Transplant Siplizumab, Exchange Transfusion, Total Body Irradiation - Anemia, Sickle Cell | Phase 1 / Phase 2 | Terminated | Columbia University | 1 | 2023-09-28 | 2026-06-10 |
| Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma Palifermin, Panobinostat, Gemcitabine - Lymphoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2017-06-01 | 2017-04-21 | |
| Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease ATG, fludarabine, cyclophosphamide - Sickle Cell Disease | Phase 2 | Recruiting | University of Illinois at Chicago | 50 | 2017-03-20 | 2026-07-08 |
| Autologous Stem Cell Study for Adult TBI (Phase 2b) Placebo Infusion, Autologous BMMNC Infusion - Brain Injuries, Traumatic, Brain Injuries, Acute | Phase 2 | Unknown | The University of Texas Health Science Center, Houston | 37 | 2016-11-21 | 2024-05-09 |
| Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) Busulfan, Fludarabine, Clofarabine - Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 11 | 2015-09-14 | 2024-02-22 |
| Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene Fludarabine, Melphalan, Alemtuzumab - Leukemia, Myeloma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2013-12-27 | 2019-07-16 |
| CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma Cyclophosphamide, Doxorubicin, Vincristine - T-cell Non-Hodgkin Lymphoma | Phase 2 | Terminated | Dana-Farber Cancer Institute | 5 | 2013-07-01 | 2023-01-30 |
| Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation Bortezomib, Carmustine, Etoposide - Multiple Myeloma | Phase 2 | Terminated | Washington University School of Medicine | 10 | 2012-09-01 | 2014-10-15 |
| Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning Fludarabine monophosphate, Busulfan, Stem Cell Infusion - Leukemia, Acute Myeloid Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 201 | 2012-04-11 | 2023-06-29 |
| Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) Fludarabine, Melphalan, Alemtuzumab - Leukemia, Lymphoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 16 | 2012-02-01 | 2016-03-17 |
| Clinical Trial I/II Opened, Randomized and Controlled for the Study of the Use of Stem Cells Therapy in Insulinized Diabetic Patients Type 2 With Critical Ischemia in Lower Limbs (CLI): Study of the Needs of Insulin Stem cell infusion - Critical Limb Ischemia (CLI) | Phase 1 / Phase 2 | Terminated | Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud | 20 | 2011-09-01 | 2018-12-19 |
| Lenalidomide and High-Dose Melphalan Lenalidomide, Melphalan, Stem Cell Infusion - Myeloma, Stem Cell Transplantation | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 61 | 2010-03-01 | 2016-06-06 |
| Safety and Effectiveness of Cord Blood Stem Cell Infusion for the Treatment of Cerebral Palsy in Children Cord Blood Infusion, Intravenous Sham - Cerebral Palsy | Phase 1 / Phase 2 | Withdrawn | Augusta University | 2010-01-01 | 2022-10-07 | |
| Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma Stem cell infusion, TLI, Anti-thymocyte globulin - Lymphoma, Non-Hodgkin | Phase 2 | Active not recruiting | Washington University School of Medicine | 18 | 2009-05-05 | 2026-02-02 |
| Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis filgrastim, bortezomib, melphalan - Multiple Myeloma | Phase 2 | Completed | Boston Medical Center | 10 | 2008-06-01 | 2017-02-06 |
| Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden Melphalan, Stem Cell Infusion, Questionnaires - Multiple Myeloma, Primary Amyloidosis | Phase 2 | Completed | M.D. Anderson Cancer Center | 80 | 2008-03-01 | 2020-01-14 |
| Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation Clofarabine, Cytarabine, Thymoglobulin - Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 2 | Terminated | Washington University School of Medicine | 7 | 2007-11-01 | 2014-09-12 |
| Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma Carboplatin, Etoposide, Melphalan - Neuroblastoma | Phase 2 / Phase 3 | Terminated | M.D. Anderson Cancer Center | 3 | 2007-10-01 | 2019-07-26 |
| Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders Campath -1H, Fludarabine, Anti-CD45 - Severe Combined Immunodeficiency Disease, Severe Primary Immunodeficiency Disorder | Phase 1 / Phase 2 | Terminated | Baylor College of Medicine | 3 | 2007-10-01 | 2013-07-02 |
Showing 20 of 35. Sign in to see all of them.
Multiple Myeloma (12) · Myelodysplastic Syndromes (8) · Leukemia, Myeloid, Acute (7) · Hodgkin Disease (6) · Leukemia (6) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (5) · Lymphoma (5) · Lymphoma, Non-Hodgkin (5) · Neoplasms, Plasma Cell (5) · Immunoglobulin Light-chain Amyloidosis (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Anemia, Aplastic (3) · Anemia, Sickle Cell (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, Follicular (2)
M.D. Anderson Cancer Center (13) · Baylor College of Medicine (6) · Boston Medical Center (3) · Masonic Cancer Center, University of Minnesota (3) · Washington University School of Medicine (3) · Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud (1) · Augusta University (1) · Columbia University (1) · Dana-Farber Cancer Institute (1) · Northwestern University (1) · The University of Texas Health Science Center, Houston (1) · University of Illinois at Chicago (1)
United States (33) · Spain (1)
Muzaffar H. Qazilbash, MD (2) · Ravi Vij, M.D. (2) · Richard E. Champlin, MD (2) · Robert Krance, MD (2) · Vaishali Sanchorawala, MD (2) · Angela Smith, MD (1) · Bernat Soria (1) · Charles S Cox, MD (1) · Damiano Rondelli, MD (1) · Daniel J. Weisdorf, MD (1) · Issa F. Khouri, MD,BS (1) · James E Carroll, M.D. (1) · Karen Quillen, MD (1) · Kathryn Leung, MD (1) · Keith Stockerl-Goldstein, MD (1)
PMID 20946966, PMID 23721329, PMID 29476021, PMID 30389035, PMID 30644983, PMID 30826465